Cerevel Therapeutics

Cerevel Therapeutics company information, Employees & Contact Information

Cerevel is now part of AbbVie. AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn for future updates.

Company Details

Employees
56
Address
1 N Waukegan Rd, North Chicago,illinois 60064,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
North Chicago, Illinois
Looking for a particular Cerevel Therapeutics employee's phone or email?

Cerevel Therapeutics Questions

News

Cerevel Therapeutics Announces Positive Topline Results for - GlobeNewswire

Cerevel Therapeutics Announces Positive Topline Results for GlobeNewswire

Cerevel Therapeutics Appoints Suneet Varma to its Board of Directors - citybiz

Cerevel Therapeutics Appoints Suneet Varma to its Board of Directors citybiz

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials - BioSpace

AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials BioSpace

Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development - Business Wire

Cerevel Therapeutics and Arya Sciences Acquisition Corp II Announce Business Combination, Creating a Publicly Listed Leader in Neuroscience Drug Development Business Wire

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion - CNBC

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion CNBC

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal - MarketWatch

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal MarketWatch

AbbVie pads neuroscience portfolio with $8.7B deal to acquire Cerevel - Fierce Biotech

AbbVie pads neuroscience portfolio with $8.7B deal to acquire Cerevel Fierce Biotech

AbbVie Acquires Cerevel Therapeutics - Contract Pharma

AbbVie Acquires Cerevel Therapeutics Contract Pharma

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors - Stock Titan

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors Stock Titan

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock - Yahoo Finance

Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock Yahoo Finance

Cerevel Therapeutics Appoints Ron Renaud as CEO - citybiz

Cerevel Therapeutics Appoints Ron Renaud as CEO citybiz

AbbVie Continues Buying Spree with $8.7B Cerevel Acquisition to Bolster Neuro - BioSpace

AbbVie Continues Buying Spree with $8.7B Cerevel Acquisition to Bolster Neuro BioSpace

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer - Yahoo Finance

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer Yahoo Finance

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon - GlobeNewswire

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon GlobeNewswire

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer - citybiz

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer citybiz

Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company - GlobeNewswire

Cerevel Therapeutics Debuts as Publicly Traded Neuroscience Company GlobeNewswire

Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors - GlobeNewswire

Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors GlobeNewswire

Cerevel Therapeutics Announces First Patients Dosed in all - GlobeNewswire

Cerevel Therapeutics Announces First Patients Dosed in all GlobeNewswire

Parkinson Disease Treatment Tavapadon Aims to Benefit From Unique Multitrial Designs - NeurologyLive

Parkinson Disease Treatment Tavapadon Aims to Benefit From Unique Multitrial Designs NeurologyLive

Rx Evolution: Pharmacological Paradigms for the Treatment of Schizophrenia - Psychiatric Times

Rx Evolution: Pharmacological Paradigms for the Treatment of Schizophrenia Psychiatric Times

Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management - Psychiatrist.com

Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management Psychiatrist.com

Emerging Treatments in Schizophrenia - Psychiatrist.com

Emerging Treatments in Schizophrenia Psychiatrist.com

Top Cerevel Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant